drugset
drugset / Trial / NCT03021395

Efficacy of Decitabine in Clearance of MRD

NCT03021395 ↗

Phase 1/2 Withdrawn Institute of Hematology & Blood Diseases Hospital, China
Non-randomizedParallel-groupOpen-labelTreatment

Summary

In this open-label, prospective clinical trial, the investigators enrolled acute myeloid leukemia (AML) patients after consolidation therapy. Patients with minimal residual disease (MRD) receive decitabine treatment if patients do not receive stem cell transplantation. The MRD clearance rate is the primary outcome to measure the efficacy of decitabine regimen.

Timeline

Start
2017-02-08
Primary completion
2021-12
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule 20 mg/m2 —

Indications

acute myeloid leukemia